This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/chemspider/
n8http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/pharmgkb/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01419/identifier/drugbank/

Statements

Subject Item
n2:DB01419
rdf:type
n3:Drug
n3:description
Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.
n3:group
approved
n3:indication
Antrafenine is used as an anti-inflammatory and analgesic agent for the relief of mild to moderate pain.
owl:sameAs
n8:DB01419 n14:DB01419
dcterms:title
Antrafenine
adms:identifier
n6:61973 n10:46507354 n11:DB01419 n12:68723 n13:Antrafenine n15:PA164784000
n3:mechanismOfAction
Antrafenine is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.
n3:synonym
Antrafenine
n3:synthesisReference
Giudicelli, D.P.R.L., Najer, H., Manory, P.M.J. and Dumas, A.P.F.; January 27,1976; assigned to Synthelabo US. Patent 3,935,229.
n3:IUPAC-Name
n4:271B489D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48A3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48A2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B489F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48A0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48A1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B489B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B489C-363D-11E5-9242-09173F13E4C5 n4:271B4899-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B489A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B48A9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48AA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48A4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48A5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48A7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48A6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48A8-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
55300-30-6
n3:Bioavailability
n4:271B48AF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48B1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B48B2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B48B3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48AE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48AD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48B0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B489E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48AB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B48AC-363D-11E5-9242-09173F13E4C5